BBIO vs USB · rev $221.9M vs P/E 12, rev $28.66B
BridgeBio Pharma Inc (BBIO) versus U.S. Bancorp (USB) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
U.S. Bancorp (USB) is a banks - regional company listed on US.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
Latest reported USB revenue for 2025-12-31 was $28.66B. Net income was $7.57B. Revenue was up 4.4% from 2024-12-31 to 2025-12-31. USB currently screens at market cap $74.68B and trailing P/E 11.9.
BBIO currently screens at market cap $13.24B. USB currently screens at market cap $74.68B and trailing P/E 11.9.
Not investment advice. Open the BBIO and USB stock pages for the full models.
Not investment advice.